Dow Chemical liable for first time in breast implant suit
This article was originally published in Clinica
Executive Summary
Dow Chemical was found liable for the first time last week for injuries alleged to have been caused by silicone breast implants manufactured by Dow Corning, its 50% joint venture with Corning. A Houston court awarded Gladys Laas and her husband $5.2 million damages, of which Dow Chemical was found liable for 20%. Lawyers for the plaintiffs presented evidence about the company's role in early silicone research and about the fact that its Italian subsidiary, Gruppo Lepetit, had distributed the devices overseas.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.